Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action

Cancer Immunology, Immunotherapy : CII
Franziska HirschhaeuserWolfgang Mueller-Klieser

Abstract

Catumaxomab is an intact trifunctional bispecific antibody targeting human EpCAM (epithelial cell adhesion molecule) and CD3 with further binding to Fcgamma receptor type I, IIa and III. We choose multicellular tumor spheroids (MCTS) of human EpCAM-positive FaDu tumor cells in co-culture with human peripheral blood mononuclear cells as an adequate three-dimensional in vitro model for pharmacological testing of catumaxomab. We found a strong dose-dependent antitumor response mediated by catumaxomab, with volume-decreased or completely destroyed tumor spheroids together with a massive immune cell infiltration and decreased signals for cancer cell viability and clonogenicity. In control experiments with F(ab')2 fragments of catumaxomab and the parental antibodies alone or in combination the effects in spheroid volume reduction were less than that of catumaxomab. All binding partners of the postulated tricell complex have to be present to exert catumaxomab's full mode of action. These distinct effects of catumaxomab are based on the unique composition of the trifunctional bispecific antibody. Since, in general, many cancers are treated by chemotherapy in combination with immunological tumor therapy, we additionally analyzed the eff...Continue Reading

References

May 29, 1996·International Journal of Cancer. Journal International Du Cancer·A KonurR Andreesen
Jun 6, 1998·International Journal of Experimental Pathology·L A Kunz-SchughartR Knuechel
Dec 22, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·M BalzarS V Litvinov
May 23, 2000·Human Pathology·C J PiyathilakeW E Grizzle
Oct 18, 2000·Critical Reviews in Oncology/hematology·W Mueller-Klieser
Jun 19, 2001·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·R RiesenbergH Lindhofer
Aug 13, 2002·Laryngo- rhino- otologie·S LangD Hölzel
May 21, 2005·International Journal of Cancer. Journal International Du Cancer·Markus M HeissHorst Lindhofer
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philipp KieweMichael Untch
Jul 28, 2006·Immunology and Cell Biology·Tao Li, Shaoheng He
Feb 3, 2007·Cancer Immunology, Immunotherapy : CII·Herbert RiechelmannMichael Schmitt
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander BurgesRainer Kimmig
Aug 13, 2008·Expert Opinion on Biological Therapy·Florian LordickDirk Jäger
Feb 12, 2009·International Journal of Cancer. Journal International Du Cancer·Thomas K HoffmannHenning Bier
Feb 14, 2009·Nature Protocols·Juergen FriedrichLeoni A Kunz-Schughart
Feb 17, 2009·Journal of Experimental & Clinical Cancer Research : CR·Michael A StröhleinMarkus M Heiss
Aug 14, 2009·Journal of Biomolecular Screening·Franziska HirschhaeuserWolfgang Mueller-Klieser

❮ Previous
Next ❯

Citations

Dec 14, 2011·Future Oncology·Juergen HessHorst Lindhofer
May 14, 2014·Advanced Drug Delivery Reviews·Christian HirtGiulio C Spagnoli
May 3, 2015·BMC Cancer·Ariane GiannattasioJoachim Koch
Mar 6, 2012·Archives of Biochemistry and Biophysics·Josée Golay, Martino Introna
Sep 13, 2011·Journal of Biomolecular Screening·Bjoern RoddayWolfgang Mueller-Klieser
Mar 12, 2019·Expert Opinion on Biological Therapy·Gerhard Hamilton, Barbara Rath
Jun 18, 2020·Biomedicines·Miltiadis FiorentzisSarah E Coupland
Oct 30, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Katharine D GruganRandall J Brezski
Sep 29, 2020·Drug Design, Development and Therapy·Lei HuangJianmin Fang
Jul 30, 2019·Frontiers in Immunology·Joanie Del BanoBrigitte Kerfelec
Nov 20, 2016·Cancer Immunology, Immunotherapy : CII·Sylvia HerterMarina Bacac
Sep 22, 2017·Journal of Hematology & Oncology·Shengnan YuKongming Wu
Jun 6, 2013·Cancer Research·Diane GoéréLaurence Zitvogel
Oct 12, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ling SongTianyan Zhou
Mar 7, 2021·International Journal of Molecular Sciences·Claire Egloff-JurasGilles Dolivet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

© 2021 Meta ULC. All rights reserved